Natural resistance of human immunodeficiency virus type 2 to zidovudine

Virology

Volumn 336, Issue 2, 2005, Pages 251-264

  Reid, Patrick ^a   MacInnes, Hamish ^a   Cong, Mian Er ^a   Heneine, Walid ^a   García Lerma, J Gerardo ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Drug resistance; HIV 2; Zidovudine

Indexed keywords

DIDANOSINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIROGENESIS; VIRUS MUTATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HIV-2; MOLECULAR SEQUENCE DATA; MUTATION; RNA-DIRECTED DNA POLYMERASE; SEQUENCE ALIGNMENT; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 18844390284     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2005.03.030     Document Type: Article

References (45)

1. C.A. Adje-Toure, R. Cheingsong, J.G. García-Lerma, S. Eholie, J.M. Bouchez, R.A. Otten, M. Sassan-Morokro, R.E. Ekpini, M. Nolan, T. Chorba, W. Heneine, and J.N. Nkengasong Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire AIDS 17 Suppl. 3 2003 S49 S54
2. F. Barre-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) Science 220 1983 868 871
3. E. Brandin, L. Lindborg, K. Gyllensten, C. Brostrom, L. Hagberg, M. Gisslen, B. Tuvesson, A. Blaxhult, and J. Albert pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy AIDS Res. Hum. Retroviruses 19 2003 543 550
4. F. Brun-Vezinet, C. Boucher, C. Loveday, D. Descamps, V. Fauveau, J. Izopet, D. Jeffries, S. Kaye, C. Zrzyanowski, A. Nunn, R. Schuurman, J. Seigneurin, C. Tamalet, R. Tedder, J. Weber, G. Weverling the National Virology Groups the Delta Virology Working Group Coordinating Committee HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta Trial Lancet 350 1997 983 990
5. F. Clavel, D. Guetard, F. Brun-Vezinet, S. Chamaret, M.A. Rey, M.O. Santos-Ferreira, A.G. Laurent, C. Dauguet, C. Katlama, C. Rouzioux, D. Klatzmann, J.L. Champalimaud, and L. Montagnier Isolation of a new human retrovirus from West African patients with AIDS Science 233 1986 343 346
6. S.W. Cox, K. Aperia, J. Albert, and B. Wahren Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations AIDS Res. Hum. Retroviruses 10 1994 1725 1729
7. J.E. Cummins Jr., J.M. Villanueva, T. Evans-Strickfaden, S.M. Sesay, S.R. Abner, T.J. Bush, T.A. Green, J.L. Lennox, T. Wright, T.M. Folks, C.E. Hart, and C.S. Dezzutti Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method J. Clin. Microbiol. 41 2003 4081 4088
8. R.T. D'Aquila, J.M. Schapiro, F. Brun-Vezinet, B. Clotet, B. Conway, L.M. Demeter, R.M. Grant, V.A. Johnson, D.R. Kuritzkes, C. Loveday, R.W. Shafer, and D.D. Richman Drug resistance mutations in HIV-1 Top. HIV Med. 11 2003 92 96
9. A. de Ronde, M. van Dooren, E. de Rooij, B. van Gemen, J. Lange, and J. Goudsmit Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient AIDS 14 2000 2632 2633
10. D. Descamps, F. Damond, S. Matheron, G. Collin, P. Campa, S. Delarue, S. Pueyo, G. Chene, F. Brun-Vezinet the French ANRS HIV-2 Cohort study group High frequency of selection of K65R and Q151M mutations in HIV-2-infected patients receiving nucleoside reverse transcriptase inhibitor-containing regimens J. Med. Virol. 74 2004 197 201
11. R.C. Gallo, S.Z. Salahuddin, M. Popovic, G.M. Shearer, M. Kaplan, B.F. Haynes, T.J. Palker, R. Redfield, J. Oleske, B. Safai, G. White, P. Foster, and P.D. Markham Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS Science 224 1984 500 503
12. R.C. Gallo, P.S. Sarin, B. Kramarsky, Z. Salahuddin, P. Markham, and M. Popovic First isolation of HTLV-III Nature 321 1986 119
13. Q. Gao, Z.X. Gu, M.A. Parniak, X.G. Li, and M.A. Wainberg In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine J. Virol. 66 1992 12 19
14. J.G. García-Lerma, P.J. Gerrish, A.C. Wright, S.H. Qari, and W. Heneine Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside resistant HIV-1 J. Virol. 74 2000 9339 9346
15. J.G. García-Lerma, S. Nidtha, K. Blumoff, H. Weinstock, and W. Heneine Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons Proc. Natl. Acad. Sci. U.S.A. 98 2001 13907 13912
16. J.G. García-Lerma, S. Nidtha, and W. Heneine Susceptibility of the human T-cell leukemia virus type 1 to reverse transcriptase inhibitors: evidence of high level resistance to lamivudine J. Infect. Dis. 184 2001 507 510
17. J.G. García-Lerma, H. MacInnes, D. Bennett, P. Reid, S. Nidtha, H. Weinstock, J.E. Kaplan, and W. Heneine A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation J. Virol. 77 2003 5685 5693
18. K. Hertogs, M. de Bethune, V. Miller, T. Ivens, P. Schel, A. van Cauwenberge, C. van den Eynde, V. van Gerwen, H. Azijn, M. van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs Antimicrob. Agents Chemother. 42 1998 269 276
19. B.A. Larder, B. Chesebro, and D.D. Richman Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents by using a quantitative plaque reduction assay Antimicrob. Agents Chemother. 34 1990 436 441
20. B.A. Larder, K.E. Coates, and S.D. Kemp Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture J. Virol. 65 1991 5232 5236
21. M.D. Larmoire, D.E. Hofheinz, N.L. Letvin, C.S. Stoner, S. Pearlman, and G.P. Toedter Detection of simian immunodeficiency virus and human immunodeficiency virus type 2 capsid antigens by a monoclonal antibody-based antigen capture assay AIDS Res. Hum. Retroviruses 9 1993 565 571
22. R.A. Otten, D.L. Ellenberger, D.R. Adams, C.A. Fridlund, E. Jackson, D. Pieniazek, and M.A. Rayfield Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (Pig-tailed macaque) model J. Infect. Dis. 180 1999 673 684
23. S.M. Owen, D. Ellenberger, M. Rayfield, S. Wiktor, P. Michel, M.H. Grieco, F. Gao, B.H. Hahn, and R.B. Lal Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry J. Virol. 72 1998 5425 5432
24. R. Pauwels, J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. de Clercq Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds J. Virol. Methods 20 1988 309 321
25. M. Petrella, and M.A. Wainberg Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Rev. 4 2002 224 232
26. M. Popovic, E. Read-Connole, and R.C. Gallo T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III Lancet 11 1984 1472 1473
27. M. Popovic, M.G. Sarngadharan, E. Read, and R.C. Gallo Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS Science 244 1984 497 500
28. S.H. Qari, S. Magre, J.G. García Lerma, A.I. Hussain, S. Takeuchi, C. Patience, R.A. Weiss, and W. Heneine Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors J. Virol. 75 2001 1048 1053
29. J.D. Reeves, and R.W. Doms Human immunodeficiency virus type 2 J. Gen. Virol. 83 2002 1253 1265
30. B. Rodes, A. Holguin, V. Soriano, M. Dourana, K. Mansinho, F. Antunes, and J. Gonzalez-Lahoz Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy J. Clin. Microbiol. 38 2000 1370 1374
31. J.C. Schmit, J. Cogniaux, P. Hermans, C. van Vaeck, S. Sprecher, B. van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. de Clercq, and A.M. Vandamme Multiple drug resistance to nucleoside analogs and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain J. Infect. Dis. 174 1996 962 968
32. T.F. Schulz, D. Whitby, J.G. Hoad, T. Corrah, H. Whittle, and R.A. Weiss Biological and molecular variability of human immunodeficiency virus type 2 isolates from the Gambia J. Virol. 64 1990 5177 5182
33. W.A. Scott The enzymatic basis for thymidine analogue resistance in HIV-1 AIDS Rev. 3 2001 194 200
34. R.W. Shafer, M.J. Kozal, M.A. Winters, A.K.N. Iversen, D.A. Katzenstein, M.V. Ragni, W.A. Meyer III, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T.C. Merigan Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations J. Infect. Dis. 169 1994 722 729
35. R.W. Shafer, A.K.N. Iversen, M.A. Winters, E. Aguiniga, D.A. Katzenstein, T.C. Merigan the AIDS Clinical Trials Group 143 Virology Team Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy J. Infect. Dis. 172 1995 70 78
36. G.M. Shaw, B.H. Hanh, S.K. Arya, J.E. Groopman, R.C. Gallo, and F. Wong-Staal Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome Science 226 1984 1165 1170
37. C. Tantillo, J. Ding, A. Jacobo-Molina, R.G. Nanni, P.L. Boyer, S.H. Hughes, R. Pauwels, K. Andries, P.A. Janssen, and E. Arnold Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance J. Mol. Biol. 243 1994 369 387
38. M.E. van der Ende, C. Guillon, P.H. Boers, T.D. Ly, R.A. Gruters, A.D. Osterhaus, and M. Schutten Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy J. Acquired Immune Defic. Syndr. 25 2000 11 18
39. M. van der Ende, J.M. Prins, K. Brinkman, M. Keuter, J. Veenstra, S.A. Danner, H.G.M. Niester, D.M.E. Osterhaus, and M. Schutten Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients AIDS 17 Suppl. 3 2003 S56 S61
40. A. Vandamme, M. Witvrouw, C. Pannecouque, J. Balzarini, K. van Laethem, J. Schmit, J. Desmyter, and E. de Clercq Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs J. Kinchington R.F. Schinazi Methods in Molecular Medicine, Antiviral Chemotherapy Protocols vol. 24 1999 Humana Press Inc. Totowa, NJ 223 258
41. M. Violin, A. Cozzi-Lepri, R. Velleca, A. Vincenti, S. d'Elia, F. Chiodo, F. Ghinelli, A. Bertoli, A. d'Arminio Monforte, C. Federico Perno, M. Moroni, and C. Balotta Risk of virological failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing HAART: the I.Co.N.A. study AIDS 18 2004 227 235
42. S. Wain-Hobson, J.P. Vartanian, M. Henry, N. Chenciner, R. Cheynier, S. Delassus, L.P. Martins, M. Sala, M.T. Nugeyre, and D. Guetard LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur Science 252 1991 961 965
43. M.A. Winters, and T.C. Merigan Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs Antimicrob. Agents Chemother. 45 2001 2276 2279
44. M. Witvrouw, C. Pannecouque, K. van Laethem, J. Desmyter, E. de Clercq, and A.M. Vandamme Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV AIDS 13 1999 1477 1483
45. M. Witvrouw, C. Pannecouque, W. Switzer, T.M. Folks, E. de Clercq, and W. Heneine Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis Antiviral Ther. 9 2004 57 65